Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2399340 | 0.87 | TRPV1 (0.54) | ALDH1A1GAASMN1; SMN2POLBMEN1 | |
| SCHEMBL6409939 | 0.86 | ALDH1A1 (0.44) | ALDH1A1TP53GAASMN1; SMN2POLB | |
| SCHEMBL2400983 | 0.83 | SMN1; SMN2 (0.44) | ALDH1A1TP53SMN1; SMN2POLBLMNA | |
| SCHEMBL2400879 | 0.82 | POLB (0.48) | ALDH1A1GAAPOLBMEN1KMT2A | |
| SCHEMBL2402458 | 0.78 | PKM (0.53) | ALDH1A1GAASMN1; SMN2POLBMEN1 | |
| SCHEMBL2401367 | 0.77 | TSHR (0.46) | ALDH1A1TP53GAASMN1; SMN2MEN1 | |
| SCHEMBL6416697 | 0.76 | CYP2C19 (0.52) | ALDH1A1GAASMN1; SMN2POLBMEN1 | |
| SCHEMBL2401314 | 0.76 | NPSR1 (0.43) | ALDH1A1MEN1KMT2ALMNATSHR | |
| SCHEMBL2401326 | 0.76 | ALDH1A1 (0.41) | ALDH1A1GAASMN1; SMN2POLBMEN1 | |
| SCHEMBL2400743 | 0.76 | ALDH1A1 (0.49) | ALDH1A1GAASMN1; SMN2POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | GRUENENTHAL GMBH (DE) | 2011-09-15 | — | — | US | claimed |
| US-8048890-B2 | Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents | GRUENENTHAL GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | GRUENENTHAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | SULT1E1, DECR1, CYP8B1 | ALDH1A1 156/4885TP53 3433/4885GAA 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.